121 related articles for article (PubMed ID: 9731198)
21. Synergistic effects with inhibitors of de novo pyrimidine synthesis, acivicin, and N-(phosphonacetyl)-L-aspartic acid.
Loh E; Kufe DW
Cancer Res; 1981 Sep; 41(9 Pt 1):3419-23. PubMed ID: 7260907
[TBL] [Abstract][Full Text] [Related]
22. Effects of PRIMA-1 on wild-type L1210 cells expressing mutant p53 and drug-resistant L1210 cells lacking expression of p53: necrosis vs. apoptosis.
Cory AH; Chen J; Cory JG
Anticancer Res; 2006; 26(2A):1289-95. PubMed ID: 16619536
[TBL] [Abstract][Full Text] [Related]
23. 2'-Deoxy-2'-methylene derivatives of adenosine, guanosine, tubercidin, cytidine and uridine as inhibitors of L1210 cell growth in culture.
Cory AH; Samano V; Robins MJ; Cory JG
Biochem Pharmacol; 1994 Jan; 47(2):365-71. PubMed ID: 8304981
[TBL] [Abstract][Full Text] [Related]
24. Cell-cycle associated transcriptional regulation of ribonucleotide reductase in L1210 leukemia cells and drug-resistant variants.
Johnson CE; Hughes K; Cory JG
Cancer Commun; 1991; 3(10-11):341-9. PubMed ID: 1760249
[TBL] [Abstract][Full Text] [Related]
25. Phenolic compounds, sodium salicylate and related compounds, as inhibitors of tumor cell growth and inducers of apoptosis in mouse leukemia L1210 cells.
Cory AH; Cory JG
In Vivo; 2005; 19(1):31-5. PubMed ID: 15796154
[TBL] [Abstract][Full Text] [Related]
26. Cross-resistance patterns in hydroxyurea-resistant leukemia L1210 cells.
Carter GL; Cory JG
Cancer Res; 1988 Oct; 48(20):5796-9. PubMed ID: 2844392
[TBL] [Abstract][Full Text] [Related]
27. Mouse leukemia L1210 cells selected for resistance to the ribonucleotide reductase inhibitor, 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone show altered response to DNA damaging agents.
Crenshaw TR; Cory JG
Int J Oncol; 1999 Sep; 15(3):487-90. PubMed ID: 10427129
[TBL] [Abstract][Full Text] [Related]
28. p53-independent anisomycin induced G1 arrest and apoptosis in L1210 cell lines.
He AW; Cory JG
Anticancer Res; 1999; 19(1A):421-8. PubMed ID: 10226577
[TBL] [Abstract][Full Text] [Related]
29. The mechanism of action of 3-deazauridine in tumor cells sensitive and resistant to arabinosylcytosine.
Brockman RW; Shaddix SC; Williams M; Nelson JA; Rose LM; Schabel FM
Ann N Y Acad Sci; 1975 Aug; 255():501-21. PubMed ID: 171997
[TBL] [Abstract][Full Text] [Related]
30. Induction of apoptosis in p53-deficient L1210 cells by an I-kappa-B-alpha-inhibitor (Bay 11-7085) via a NF-kappa-B-independent mechanism.
Cory AH; Cory JG
Adv Enzyme Regul; 2005; 45():85-93. PubMed ID: 16129475
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of drug resistance to inhibitors directed at the individual subunits of ribonucleotide reductase.
Carter GL; Thompson DP; Cory JG
Cancer Commun; 1989; 1(1):13-20. PubMed ID: 2701080
[TBL] [Abstract][Full Text] [Related]
32. Deoxyadenosine toxicity and cell cycle arrest in hydroxyurea-resistant S49 T-lymphoma cells.
Albert DA; Nodzenski E
Exp Cell Res; 1988 Dec; 179(2):417-28. PubMed ID: 3056732
[TBL] [Abstract][Full Text] [Related]
33. Selection and characterization of mutant S49 T-lymphoma cell lines resistant to phosphonoformic acid: evidence for inhibition of ribonucleotide reductase.
Albert DA; Gudas LJ
J Cell Physiol; 1986 May; 127(2):281-7. PubMed ID: 2939095
[TBL] [Abstract][Full Text] [Related]
34. Antitumor activity of the weekly intravenous push schedule of 5-fluoro-2'-deoxyuridine +/- N-phosphonacetyl-L-aspartate in mice bearing advanced colon carcinoma 26.
van Laar JA; Durrani FA; Rustum YM
Cancer Res; 1993 Apr; 53(7):1560-4. PubMed ID: 8453623
[TBL] [Abstract][Full Text] [Related]
35. Resistance to cyclopentenylcytosine in murine leukemia L1210 cells.
Zhang H; Cooney DA; Zhang MH; Ahluwalia G; Ford H; Johns DG
Cancer Res; 1993 Dec; 53(23):5714-20. PubMed ID: 7694793
[TBL] [Abstract][Full Text] [Related]
36. Antineoplastic effect of the combination of 2,3-dihydro-1H-pyrazole[2,3a]imidazole plus deoxyadenosine/erythro-9-(2-hydroxyl-3-nonyl)adenine in mice with L1210 leukemia cells.
Matsumoto M; Weckbecker G; Cory JG
Cancer Commun; 1990; 2(1):1-6. PubMed ID: 2369548
[TBL] [Abstract][Full Text] [Related]
37. Effects of combinations of drugs having different modes of action at the ribonucleotide reductase site on growth of L1210 cells in culture.
Sato A; Carter GL; Bacon PE; Cory JG
Cancer Res; 1982 Nov; 42(11):4353-7. PubMed ID: 6751522
[TBL] [Abstract][Full Text] [Related]
38. In vivo growth of mouse leukemia L1210 cells with metabolic alterations in the subunits of ribonucleotide reductase.
Somerville L; Cory AH; Cory JG
In Vivo; 2002; 16(3):175-7. PubMed ID: 12182112
[TBL] [Abstract][Full Text] [Related]
39. Macrophage inhibitory cytokine 1 mediates a p53-dependent protective arrest in S phase in response to starvation for DNA precursors.
Agarwal MK; Hastak K; Jackson MW; Breit SN; Stark GR; Agarwal ML
Proc Natl Acad Sci U S A; 2006 Oct; 103(44):16278-83. PubMed ID: 17050687
[TBL] [Abstract][Full Text] [Related]
40. Selective inhibition of pyrimidine synthesis and depletion of nucleotide pools by N-(phosphonacetyl)-L-aspartate.
Moyer JD; Handschumacher RE
Cancer Res; 1979 Aug; 39(8):3089-94. PubMed ID: 455293
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]